Scarica l'app Stockscreener
71.86
1.05%
0.7339
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension Trial - Yahoo Finance
AstraZeneca’s NeoCOAST-2 Study: A New Horizon in Lung Cancer Treatment - TipRanks
AstraZeneca’s Latest Clinical Study on NSCLC: Key Insights for Investors - TipRanks
AstraZeneca’s ARTEMIDE-Lung03: A Promising Phase III Study in Lung Cancer Treatment - TipRanks
AstraZeneca’s Phase II Study on AZD4604: A Potential Breakthrough in Asthma Treatment - TipRanks
AstraZeneca blood pressure drug succeeds in late-stage trial - BioPharma Dive
AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Breakthrough in CKD Treatment - TipRanks
AstraZeneca reports positive Phase III results for baxdrostat in hypertension - Investing.com
AstraZeneca’s Baxdrostat hits all Phase III endpoints, eyes 2025 filing | AZN SEC FilingForm 6-K - Stock Titan
Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo
AstraZeneca's baxdrostat meets key goals in late-stage trial for hypertension - Seeking Alpha
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial - Benzinga
Astrazeneca's Phase 3 Trial of Baxdrostat in Hypertension Meets Primary, Secondary Endpoints - MarketScreener
AstraZeneca gains on successful trial for blood pressure drug, 14 Jul 2025 11:30 - Shares Magazine
AstraZeneca drug lowers high blood pressure in late-stage study; shares rise - MarketScreener
Astra says potential blockbuster reduced high blood pressure - Moneycontrol
AstraZeneca says potential blockbuster reduced high blood pressure - The Edge Malaysia
AstraZeneca: conclusive results against hypertension - MarketScreener
AstraZeneca shares gain after drug shows success in late-stage hypertension trial - Investing.com UK
AstraZeneca drug lowers high BP in late-stage study; shares rise - MarketScreener
AstraZeneca drug meets all goals in high blood pressure study - MarketScreener
AstraZeneca says baxdrostat met primary and secondary endpoints in Phase III trial - MarketScreener
AstraZeneca's Baxdrostat Meets Phase III Endpoints In Hypertension Trial - DirectorsTalk Interviews
An AstraZeneca Exit Wouldn’t Doom London - Bloomberg.com
AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React - Stocktwits
AstraZeneca’s New Study on CKD Treatment: Potential Market Impacts - The Globe and Mail
AstraZeneca’s Tozorakimab Study: A New Frontier in Drug Delivery - The Globe and Mail
AstraZeneca’s Innovative Cancer Study: AZD7789’s Potential Impact - The Globe and Mail
AstraZeneca’s SERENA-1 Study: A New Hope for Advanced Breast Cancer Treatment - TipRanks
AstraZeneca Completes Key Study on Asthma and COPD Diagnostics - TipRanks
AstraZeneca Completes Key Study on Hyperkalemia Management in Heart Failure - TipRanks
AstraZeneca’s PRIMULA Preg Study: Assessing Anifrolumab’s Impact on Pregnancy Outcomes - TipRanks
AstraZeneca’s Osimertinib Study Update: Potential Market Impact - The Globe and Mail
AstraZeneca’s TROPION-PanTumor03: A Promising Phase II Study in Oncology - TipRanks
AstraZeneca’s TRIXEO Study: Real-World Insights into COPD Treatment - TipRanks
AstraZeneca’s CKD Registry Study: A New Frontier in Chronic Kidney Disease Research - TipRanks
AstraZeneca’s Latest Study on AZD4248: A Potential Game-Changer in Diabetes and Kidney Disease Treatment - TipRanks
AstraZeneca’s Latest Study on AZD2389: What Investors Need to Know - TipRanks
AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead - Proactive Investors
Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong - GlobeNewswire Inc.
AstraZeneca’s SERENA-1 Study: A Promising Development in Breast Cancer Treatment - TipRanks
AstraZeneca’s UmbREALung Study: Real-World Insights into NSCLC Treatment - TipRanks
AstraZeneca’s Real-world Study on Anifrolumab: Implications for Investors - TipRanks
Eli Lilly and AstraZeneca’s Promising Study on KRAS G12C-Mutant Lung Cancer - TipRanks
AstraZeneca’s CAR-T Therapy Study for Liver Cancer: Key Insights for Investors - TipRanks
AstraZeneca’s Innovative PET Study on Crohn’s Disease: Market Implications and Progress - TipRanks
AstraZeneca’s Observational Study on Tezepelumab: A New Hope for Severe Asthma Patients - TipRanks
AstraZeneca’s PROGRESS-CKD Study: A Step Forward in Understanding Hypertension and Kidney Disease - TipRanks
AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor - Yahoo
AstraZeneca’s ASCENT Study: Real-World Insights on Tezepelumab for Severe Asthma - TipRanks
AstraZeneca’s NASH Study Completes: Market Implications of AZD4831 - TipRanks
AstraZeneca’s Latest Study on Inhaler Propellants: Key Insights for Investors - TipRanks
AstraZeneca’s Real-World Study on Dapagliflozin: A Strategic Move in Heart Failure Treatment - TipRanks
AstraZeneca’s Acalabrutinib Study: A Promising Update for B-cell Malignancies - TipRanks
AstraZeneca’s New CKD Study: A Potential Game-Changer? - TipRanks
AstraZeneca’s SZC Study Completion: Impact on Hyperkalemia Management - TipRanks
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal - Yahoo Finance
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank - Proactive Investors
AstraZeneca PLC (AZN) Partners Modella AI for AI Drug Development - Insider Monkey
AstraZeneca (AZN) Announces Strategic Research Collaboration with CSPC Pharmaceuticals - MSN
The Zacks Analyst Blog Highlights T-Mobile US, AstraZeneca and Comcast - Yahoo Finance
AstraZeneca’s Phase 3 Breast Cancer Study: Key Updates and Market Implications - TipRanks
Top Analyst Reports for T-Mobile, AstraZeneca & Comcast - Yahoo Finance
AstraZeneca’s Tozorakimab Study: A New Phase in Drug Delivery - TipRanks
AstraZeneca’s Phase 2 Study on TAK-341 for Multiple System Atrophy: Key Insights for Investors - TipRanks
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth? - Yahoo Finance
AstraZeneca: Just What The Doctor Ordered (NASDAQ:AZN) - Seeking Alpha
AstraZeneca’s Ondexxya Study: A Closer Look at Safety and Effectiveness - TipRanks
AstraZeneca’s SERENA-4 Study: A New Hope in Breast Cancer Treatment - TipRanks
Why AstraZeneca Stock Got Thumped on Thursday - AOL.com
Summit Is in Talks for $15 Billion Partnership With AstraZeneca - Bloomberg.com
London’s New Listings Hit 28-Year Low as AstraZeneca Weighs Exit - Bloomberg.com
Why AstraZeneca Stock Topped the Market on Tuesday - MSN
AstraZeneca Rises on Report CEO Wants to Move Listing to US - Bloomberg.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):